Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15978955 | 0.92 | L3MBTL1 (0.62) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969582 | 0.92 | L3MBTL1 (0.71) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969545 | 0.88 | MEN1 (0.69) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969485 | 0.87 | MEN1 (0.64) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969530 | 0.87 | L3MBTL1 (0.57) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969988 | 0.85 | L3MBTL1 (0.83) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15969960 | 0.85 | MEN1 (0.55) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15978956 | 0.84 | MAPT (0.68) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL15968979 | 0.83 | L3MBTL1 (0.57) | L3MBTL1KDM4ELMNAHTTALOX15 | |
| SCHEMBL13440900 | 0.82 | L3MBTL1 (0.87) | L3MBTL1KDM4ELMNAHTTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8946430-B2 | Quinolinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | L3MBTL1 3619/4885KDM4E 483/4885LMNA 726/4885 |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | L3MBTL1 3619/4885KDM4E 483/4885LMNA 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.